- Home
- HOOK
HOOK
HOOKIPA Pharma Inc.
as 05-20-2024 4:00pm EST
$.
+$.
+.%
HOOKIPA Pharma Inc is a clinical stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. It uses off-the-shelf technologies, VaxWave and TheraT, to elicit directly within patients a response of antigen-specific killer T cells and antibodies.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 80.7M | IPO Year: | 2019 |
| Target Price: | $4.06 | AVG Volume (30 days): | 794.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.50 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.41 - $1.57 | Next Earning Date: | 05-09-2024 |
| Revenue: | $53,552,000 | Revenue Growth: | 235.12% |
| Revenue Growth (this year): | 66.71% | Revenue Growth (next year): | -54.62% |
Share on Social Networks:
Latest HOOKIPA Pharma Inc. News
HOOK Breaking Stock News: Dive into HOOK Ticker-Specific Updates for Smart Investing
Simply Wall St.
9 days ago
HOOKIPA Pharma First Quarter 2024 Earnings: Beats Expectations
GlobeNewswire
11 days ago
HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
GlobeNewswire
25 days ago
HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab
Benzinga
a month ago
Why Is Penny Stock HOOKIPA Pharma Trading Higher On Wednesday?
GlobeNewswire
a month ago
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers
GlobeNewswire
a month ago
HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
a month ago
HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration
Simply Wall St.
2 months ago